newsfilter
← Latest News
GlobeNewswire·

Revive Therapeutics Provides Update of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19

TORONTO, May 30, 2023 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB:RVVTF) (CSE:RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of